NCT00351949View on ClinicalTrials.gov

IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

October 31, 2008

Conditions
Stage IV Renal Cell Carcinoma
Interventions
BIOLOGICAL

IMP321

subcutaneous injections of IMP321 every 14 days for three months (6 injections. Doses tested: 50, 250, 1,250, 6,250 or 30,000 µg

Trial Locations (1)

94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
collaborator

Umanis

INDUSTRY

lead

Immutep S.A.S.

INDUSTRY

NCT00351949 - IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) | Biotech Hunter | Biotech Hunter